Profile data is unavailable for this security.
About the company
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
- Revenue in USD (TTM)33.59m
- Net income in USD-44.37m
- Incorporated2003
- Employees102.00
- LocationNanobiotix SA60 rue de WattigniesPARIS 75012FranceFRA
- Phone+33 140260470
- Fax+33 140260444
- Websitehttps://www.nanobiotix.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gossamer Bio Inc | 95.84m | -80.85m | 215.37m | 135.00 | -- | 2.64 | -- | 2.25 | -0.3996 | -0.3996 | 0.434 | 0.3604 | 0.3453 | -- | -- | 709,940.80 | -29.13 | -57.43 | -34.41 | -64.38 | -- | -- | -84.36 | -- | -- | -7.07 | 0.7073 | -- | -- | -- | 21.61 | -- | -- | -- |
Codexis Inc | 60.89m | -76.36m | 219.87m | 174.00 | -- | 3.58 | -- | 3.61 | -1.09 | -1.09 | 0.8723 | 0.8665 | 0.3595 | 6.27 | 3.58 | 349,942.50 | -45.08 | -17.13 | -56.05 | -20.23 | 77.95 | 77.29 | -125.41 | -37.04 | 2.92 | -- | 0.3158 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Pyxis Oncology Inc | 16.15m | -59.20m | 221.05m | 51.00 | -- | 1.29 | -- | 13.69 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 221.84m | 145.00 | -- | 1.49 | -- | 3.08 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
Acrivon Therapeutics Inc | 0.00 | -69.00m | 224.86m | 58.00 | -- | 1.04 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Candel Therapeutics Inc | 0.00 | -49.99m | 224.91m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 226.52m | 112.00 | -- | 0.6792 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
Mersana Therapeutics Inc | 29.94m | -104.77m | 226.95m | 123.00 | -- | 26.93 | -- | 7.58 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Omeros Corp | 0.00 | -199.92m | 227.15m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Trevi Therapeutics Inc | 0.00 | -38.77m | 228.66m | 25.00 | -- | 3.46 | -- | -- | -0.3879 | -0.3879 | 0.00 | 0.9116 | 0.00 | -- | -- | 0.00 | -44.37 | -47.39 | -47.48 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0014 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Nanobiotix SA - ADR | 33.59m | -44.37m | 232.02m | 102.00 | -- | -- | -- | 6.91 | -1.23 | -1.23 | 0.9097 | -0.0437 | 0.3912 | -- | 19.59 | 329,343.00 | -51.67 | -- | -120.56 | -- | -- | -- | -132.08 | -- | -- | -1.98 | 1.04 | -- | -- | -- | 30.40 | -- | -- | -- |
Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 239.63m | 449.00 | -- | 2.49 | -- | 1.69 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Amarin Corporation plc (ADR) | 264.78m | -33.52m | 239.66m | 275.00 | -- | 0.4345 | -- | 0.9051 | -0.082 | -0.082 | 0.6466 | 1.34 | 0.319 | 0.4395 | 2.15 | 962,832.80 | -4.04 | -4.48 | -5.79 | -6.54 | 61.29 | 75.70 | -12.66 | -8.59 | 2.01 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
enGene Holdings Inc | 0.00 | -123.44m | 243.19m | 33.00 | -- | 1.06 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
2Seventy Bio Inc | 44.12m | -156.25m | 245.13m | 274.00 | -- | 1.04 | -- | 5.56 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Data as of Sep 27 2024. Currency figures normalised to Nanobiotix SA's reporting currency: US Dollar USD
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 30 Jun 2024 | 2.87m | 6.09% |
Perceptive Advisors LLCas of 31 Mar 2024 | 555.07k | 1.18% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 253.45k | 0.54% |
UBS Financial Services, Inc.as of 31 Mar 2024 | 3.10k | 0.01% |
GAMMA Investing LLCas of 30 Jun 2024 | 2.03k | 0.00% |
Qube Research & Technologies Ltd.as of 31 Mar 2024 | 619.00 | 0.00% |
Tower Research Capital LLCas of 31 Mar 2024 | 450.00 | 0.00% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 262.00 | 0.00% |
RBC Dominion Securities, Inc.as of 31 Mar 2024 | 34.00 | 0.00% |
RhumbLine Advisers LPas of 30 Jun 2024 | 33.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.